Insmed Appoints Former Sanofi CEO Paul Hudson and Verily CFO Utpal Koppikar to Board of Directors

Executive Summary

On October 16, 2026, the Board of Directors of Insmed Incorporated (Nasdaq: INSM) appointed Paul Hudson and Utpal Koppikar as new independent directors, effective October 19, 2026. The appointments add seasoned pharmaceutical leadership, commercial execution experience, and biopharma financial expertise to Insmed's board.

Director Backgrounds and Committee Assignments

• Paul Hudson (Class II Director, Compensation Committee):
  • Served as Chief Executive Officer of Sanofi S.A. from September 2019 through February 2026.
  • Previously served as CEO of Novartis Pharmaceuticals (2016–2019) and held executive commercial roles at AstraZeneca, including President of AstraZeneca United States.
• Utpal Koppikar (Class I Director, Audit Committee):
  • Currently serves as Chief Financial Officer of Verily Health Inc. (since April 2023).
  • Previously served as Executive Vice President and CFO of Atara Biotherapeutics (2018–2023), with prior financial leadership positions at Gilead Sciences and Amgen.
  • Currently serves on the board of C4 Therapeutics, Inc. (Nasdaq: CCCC).

Both directors are scheduled to stand for election at Insmed's 2027 Annual Meeting of Shareholders.

Compensation Arrangements

Under Insmed's non-employee director compensation framework:

• Cash Compensation:
  • Annual Board retainer of $65,000 (prorated for 2026).
  • Additional annual committee retainer of $12,500 each ($12,500 for Hudson on Compensation Committee; $12,500 for Koppikar on Audit Committee, prorated for 2026).
• Equity Compensation:
  • Initial grant of Restricted Stock Units (RSUs) with an aggregate grant date fair value of approximately $585,000 each.
  • RSUs vest in three equal annual installments on each of the first three anniversaries of the award date, contingent upon continuous board service.

Market and Governance Impact

• Governance Strength: Adding the former CEO of a global top-tier biopharma firm (Sanofi) and an experienced public life sciences CFO significantly enhances the board's strategic oversight capabilities during Insmed's ongoing commercial and pipeline expansion.
• Trading Significance: Classified as Low. Routine director appointments and standard non-employee director equity packages generally do not create immediate short-term share price catalysts, although the caliber of board appointments provides positive long-term corporate governance signals.